Amarin expects U.S. volumes to remain stable through 2026 while Europe demand rises 68%

• "As we approach the end of the year" CEO, President & Director Aaron Berg said the company carried first-half momentum into Q3 with "profitable third quarter results, reductions in our expense profile, continued positive operating cash flow, a stronger cash position and 0 debt" (CEO, President & Director Aaron Berg).
• Berg framed international growth as partner-led, stating, "Our partners are expanding the global reach of VASCEPA and VAZKEPA and driving double-digit in-market demand growth," and adding that under Recordati, VAZKEPA was commercialized in 11 European countries as of September 30, with an October Poland launch on a private-pay basis (CEO, President & Director Berg).
• In the U.S., Berg said Amarin "maintained our leading position in the U.S. IPE market with a 47% share" and emphasized payer dynamics and near-term volume stability: "We continue to expect to maintain our exclusivity with key payers through the end of 2026 and expect U.S. volumes to remain stable through year-end" (CEO, President & Director Berg).
• CFO Peter Fishman attributed the quarter’s profitability to restructuring and the commercial model: "We reported our first profitable quarter in 2 years, reflecting the benefits of our completed restructuring as well as our company-managed U.S. and fully partnered international commercial model" (Senior VP & CFO Peter Fishman).
• On R&D and potential label expansion themes, management highlighted the EMT2 investigator-initiated Phase III study in colorectal cancer liver metastases; R&D head Steven Ketchum said, "while the primary endpoint of progression-free survival was not met, the study demonstrated an improvement in the key secondary endpoint of overall survival" and described "a statistically significant 32% lower hazard of death" (Executive VP, President of Research & Development and Chief Scientific Officer Steven Ketchum).

Outlook

• Management reiterated near-term U.S. access expectations and volume stability, with Berg stating, "We continue to expect to maintain our exclusivity with key payers through the end of 2026 and expect U.S. volumes to remain stable through year-end" (CEO, President & Director Berg).
• On pricing, Fishman said, "we expect the pricing to remain relatively consistent through the end of this year," and added, "While we haven't given guidance on '27... We have seen that continued pricing pressure over previous years and would anticipate that to continue into '27" (Senior VP & CFO Fishman).
• On capital deployment, Berg linked decisions to ongoing adviser work: "These discussions and their potential outcomes will inform the timing, scale and prioritization of future capital deployment activities such as a share repurchase" (CEO, President & Director Berg).
• Analysts’ estimates comparison was omitted because the provided estimates data did not include a valid fiscalQuarter format (Q1–Q4).

Financial Results

• Fishman reported total net revenue of $39.6M (product revenue $36.9M; licensing and royalty revenue $2.7M) and said U.S. product revenue was $28.5M, with the year-over-year decline reflecting "lower net selling prices" tied to customer mix and "generic competition" (Senior VP & CFO Fishman).
• Profitability and cash were central themes: Fishman reported net income of $245,000 (less than $0.01 per share) and said, "We generated positive operating cash flow for the third quarter of $9 million"; he also stated cash and investments ended September at $324M, "an increase of $21 million from year-end 2025 and remain debt-free" (Senior VP & CFO Fishman).
• Cost and margin commentary focused on supply changes and variability: Fishman said Q3 cost of goods sold was $23.4M and noted "the early benefits of our renegotiated supply contracts," including "a sequential gross margin improvement excluding write-offs of approximately 2.3 percentage points" despite U.S. pricing pressure (Senior VP & CFO Fishman).
• On operating expenses, Fishman said total operating expense declined 44% year-over-year, helped by "no restructuring expenses during the quarter compared to $9.4 million last year"; he added inventory declined "by 31% from Q4 2024" (Senior VP & CFO Fishman).

Q&A

• Jessica Fye, JPMorgan Chase & Co, Research Division: "I didn't catch the branded prescription growth that usually comes in the press release this quarter. Can you comment on that? How do we reconcile U.S. script volume growth with the decline in U.S. revenues year-over-year?" CEO Berg: "The volume for the branded VASCEPA was stable. It was relatively flat. The downward impact on revenue was due to pricing pressure" (CEO, President & Director Berg).
• Fye, JPMorgan Chase & Co, Research Division: "can you just give us a little bit of a sense about how to think about the U.S. price trajectory" CFO Fishman: "we expect the pricing to remain relatively consistent through the end of this year" and "would anticipate" continued pricing pressure into 2027 while awaiting "final confirmation" on exclusives (Senior VP & CFO Fishman).
• Kyuwon Choi, Goldman Sachs Group, Inc., Research Division: asked for "any updates in terms of reimbursement and coverage in major European markets" and Amarin’s criteria for additional therapeutic applications and partnering. CEO Berg said Recordati is progressing broadly across its 59-country scope and cited France as "a very lengthy process," while on EMT2 he said, "we just saw the data ourselves" and that Amarin will assess "the commercial opportunity, what's the unmet need, what data already exists, what can we do to protect it" and manage decisions "very disciplined" (CEO, President & Director Berg).

Sentiment Analysis

• Analysts’ tone was neutral to slightly skeptical, with JPMorgan pressing on the absence of disclosed branded prescription growth and explicitly probing the mismatch between "script volume growth" and declining U.S. revenue, plus follow-up on the U.S. price trajectory (Jessica Fye, JPMorgan Chase & Co, Research Division).
• Management’s prepared-remarks tone was positive and confident on cash generation and partner-led demand, while Q&A responses were more cautious on pricing and 2027 visibility, including, "we haven't given guidance on '27" and "still waiting for final confirmation" (Senior VP & CFO Fishman).
• Versus Q2, management maintained similar confidence in the partnered model and cost structure, but Q3 introduced more explicit discussion of continued pricing pressure and highlighted EMT2 as a new scientific development shaping future evaluation (CEO, President & Director Berg; Executive VP, President of Research & Development and Chief Scientific Officer Ketchum).

Quarter-over-Quarter Comparison

• Q3 emphasized a profitability milestone ("first profitable quarter in 2 years") and four consecutive quarters of positive operating cash flow, whereas Q2 emphasized an "inflection point" and the initiation of providing "an outlook for certain key metrics for full-year 2026" (Senior VP & CFO Fishman; CEO, President & Director Berg).
• U.S. share commentary shifted from 48% in Q2 (as of June 30) to 47% in Q3, with both quarters stressing payer exclusivity through 2026 and stable volumes expectations (CEO, President & Director Berg).
• International demand growth remained a central narrative in both quarters (Europe in-market demand 69% in Q2 vs. 68% in Q3), while Q3 added greater detail on how partner ordering patterns can decouple reported revenue from in-market demand and urged a trailing 12-month lens (Senior VP & CFO Fishman).
• Analyst focus was consistent on Europe reimbursement (Goldman Sachs in both quarters), while Q3 added sharper scrutiny on U.S. pricing and the absence of a commonly reported branded prescription growth metric (JPMorgan).

Risks and Concerns

• Management cited "U.S. pricing pressure" and said revenue can be influenced by "the timing of partner orders" under the partnered model (CEO, President & Director Berg).
• Fishman cautioned that partner purchases "can vary quarter-to-quarter" based on "partner inventory levels and ordering patterns" and said gross margin "may vary from quarter-to-quarter based on sales mix and the timing and volume of partner shipments" (Senior VP & CFO Fishman).
• On 2027 U.S. pricing visibility, Fishman said the company is "still waiting for final confirmation" on exclusives going into 2027 (Senior VP & CFO Fishman).

Final Takeaway

Management described Q3 as a turning point on profitability and cash, attributing results to a lower cost structure, supply contract improvements, and a partner-driven international expansion model, while acknowledging that U.S. pricing pressure and partner ordering cadence can drive reported revenue volatility. Leadership reiterated expectations for U.S. payer exclusivity through the end of 2026 and stable volumes through year-end, positioned Recordati’s broader European rollout as a key growth lever, and said ongoing discussions with Barclays will shape the timing and scale of potential capital deployment actions such as a share repurchase.

Read the full Earnings Call Transcript

Seeking Alpha's Disclaimer: This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.